Medication & Safety
How Much Does Ozempic Cost? A Country-by-Country Guide
Ozempic costs $800–$1000 per month in the US without insurance. Costs vary widely globally. Here is the complete breakdo...
The STEP 1 clinical trial — the largest study of semaglutide for weight loss — showed an average of 14.9% body weight reduction over 68 weeks at the 2.4 mg dose. For a person starting at 100 kilograms, that is approximately 15 kilograms. One in three participants lost more than 20% of their starting weight. These are results that no other non-surgical weight loss approach has matched consistently.
But averages conceal a wide range. Individual results on Ozempic vary from near-zero to more than 25% body weight loss. Understanding what drives that variation is what separates realistic expectations from disappointment.
What the Clinical Trials Show
The STEP programme included four major trials, each producing different average results based on the population tested:
STEP 1 (non-diabetics, 2.4 mg): 14.9% average weight loss over 68 weeks. This is the headline number cited in most coverage of Ozempic.
STEP 2 (type 2 diabetics, 2.4 mg): 9.6% average weight loss. Insulin resistance reduces the metabolic response.
STEP 3 (non-diabetics with intensive behavioural support): 16% average weight loss. Structured dietary support amplifies the drug's effect.
STEP 4 (maintenance after 20 weeks): Participants who stopped semaglutide regained most weight within a year. Continuing treatment maintained the loss.
What Drives Your Personal Result
Dose: The single strongest predictor. At 0.5 mg, average loss is around 5%. At 1 mg, around 8%. At 2.4 mg, around 15%. If your prescription caps at 1 mg, your expected result is roughly half the STEP 1 headline.
Diabetes status: Type 2 diabetics lose roughly 5 percentage points less than non-diabetics at the same dose. Insulin resistance reduces the metabolic flexibility that efficient fat loss requires.
Protein intake: People who increase dietary protein to 1.2 to 1.6g per kilogram of body weight lose more weight and lose more fat relative to muscle. Protein also reduces the muscle mass loss that accounts for a significant portion of total weight lost on GLP-1 drugs.
Exercise: Adding resistance training three times per week to semaglutide treatment increases fat loss and substantially reduces muscle loss. The STEP 3 trial showed 16% average loss with structured dietary and activity support — versus 14.9% with medication alone.
Duration: Peak weight loss occurs around week 60 to 68. People who stop at week 12 or 16 achieve far less than those who complete the full course.
Monthly Weight Loss Expectations
A practical breakdown, based on clinical trial data and real-world prescribing experience:
- Month 1 (0.25 mg starter dose): 1 to 2 kg
- Month 2 (0.5 mg): 2 to 3 kg cumulative additional
- Months 3 to 6 (1 mg): 0.5 to 1 kg per week on average
- Months 7 to 16 (2 mg or 2.4 mg): Plateau risk increases; consistent loss continues with dietary support
What Real Pakistani Patients Report
Members of the METASLIM physician-guided GLP-1 program in Pakistan — which delivers GLP-1 pathway support through sublingual drops — report an average of 8 to 22 kilograms over the 8-week program. This variation reflects the same factors described above: starting BMI, dietary protein, activity level, and individual metabolic response. Use our BMI calculator to track your starting point before beginning any program.